Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. The company’s founders are leading experts in small molecule therapeutics development for RNA-based disease. Their first drug candidates are targeted towards cancers and neurological conditions. Skyhawk Therapeutics recently appointed Dr. Elliot Ehrich as its President, and Dr. Graeme Smith as its Senior Vice President of Nonclinical Development.